GlassScriptPhysician profile
Nora Jane Bucher
NPI 1942416524
$113,249.71
in general payments reported to CMS, 2019-2025
28 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,288 · 2020: $112 · 2021: $7,071 · 2022: $9,220 · 2023: $51K · 2024: $17K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $22K · Travel and Lodging: $8,253 · Food and Beverage: $2,226 · Honoraria: $1,039 · Education: $30.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,350.00 |
| Consulting Fee | $21,660.50 |
| Travel and Lodging | $8,252.60 |
| Food and Beverage | $2,226.42 |
| Honoraria | $1,038.77 |
| Education | $30.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $47,389.21 | 2023-2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $30,295.66 | 2021-2025 | Tagrisso, Imfinzi |
| Genentech USA, INC. | $13,342.69 | 2019-2024 | Lunsumio, Venclexta, Polivy |
| Incyte Corporation | $3,412.49 | 2023 | |
| Karyopharm Therapeutics INC. | $3,260.00 | 2023 | Xpovio |
| Abbvie INC. | $2,100.00 | 2025 | |
| Beigene USA, INC. | $1,950.00 | 2023 | Brukinsa |
| Tesaro, INC. | $1,852.08 | 2019 | |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Genentech, INC. | $1,515.00 | 2023 | Venclexta |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Daiichi Sankyo INC. | $1,429.75 | 2022 | |
| Epizyme, INC. | $1,181.95 | 2021-2022 | |
| Janssen Global Services, LLC | $945.00 | 2023 | Erleada |
| Macrogenics, INC. | $592.00 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $186.05 | 2019 | |
| Novocure INC. | $148.25 | 2019-2025 | Optune Gio, Optune |
| E.R. Squibb & Sons, L.L.C. | $108.66 | 2019 | |
| Geron Corporation | $105.54 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2020 | |
| Amgen INC. | $52.88 | 2019-2020 | |
| Emd Serono, INC. | $20.57 | 2019 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.30 | 2025 | |
| Puma Biotechnology, INC. | $12.71 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Bucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.